Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 70/100

Indivior Announces Q3 2023 Financial Results Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor...

Key Takeaway: Indivior PLC has released its financial results for the third quarter of 2023, reflecting ongoing progress in its operations. The company is focused on addressing substance use disorders and aims to provide global access to evidence-based treatments. Indivior's commitment to innovation and expansion in therapeutic options is highlighted, as it continues to work on a pipeline of products targeting various conditions. A live webcast presentation of the financial results is scheduled for later today.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior reported its financial results for Q3 2023, showcasing growth.
  • The company continues to work on expanding its portfolio for substance use disorders and other chronic conditions.
  • Indivior emphasizes its commitment to treating substance use disorders globally.

Full Press Release Details

SLOUGH, United Kingdom and RICHMOND, Va. , Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV ) today announced its financial results for the period ending September 30, 2023 . The earnings release, investor presentation and webcast are available at www.indivior.com .
There will be a live webcast presentation at 13:00 BST ( 8:00 am EST ) hosted by Mark Crossley , CEO. The details are below.
Webcast link: https://edge.media-server.com/mmc/p/stcq4w5c Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BIf8e71289ddc241b399540e669d753461
(Please note this is a change from prior calls - registrants will have an option to be called back directly immediately prior to the call or be provided a call-in # with a unique pin code following their registration)
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA , Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior .

21 %

Frequently Asked Questions

When did Indivior announce its financial results?

Indivior announced its financial results on November 9, 2023.

How can I access the live webcast presentation?

You can access the webcast presentation at 13:00 BST using the provided link.

What type of disorders does Indivior focus on treating?

Indivior focuses on treating substance use disorders and serious mental illnesses.

Where is Indivior headquartered?

Indivior is headquartered in Richmond, Virginia, USA.

In how many countries are Indivior's products available?

Indivior's products are available in 37 countries worldwide.

Last updated: Nov 9, 2023